Highlights 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
7.89 ^USD	+1.41%		-3.07%	-29.36%

May. 22	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress	CI
May. 14	89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress	May. 22	CI
89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	May. 14	CI
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	Mar. 27	MT
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	Mar. 27	CI
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	Mar. 12	CI
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	Dec. 04	CI
89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis	Nov. 27	CI
89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis	Nov. 12	CI
89bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
89bio Says US FDA Grants Breakthrough Therapy Label for Pegozafermin in Nonalcoholic Steatohepatitis	23-09-21	MT
89bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis	23-06-24	CI
89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia	23-05-23	CI
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
89bio, Inc. Announces Positive Topline Data from the Phase 2b ENLIVEN Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis	23-03-22	CI
89bio's Q4 Net Loss Narrows	23-03-10	MT
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-10	CI
89bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 89bio, Inc.

Equities

ETNB

US2825591033

Highlights

Filters